132results about How to "Good cell permeability" patented technology

The invention relates to apparatus and method for ultrasonically and electromagnetically treating tissue to treat, for example, traumatized tissue or a bone injury. The apparatus includes at least one ultrasonic transducer assembly and at least one electromagnetic coil-assembly configured to cooperate with a placement module for placement in proximity to the treatment area. The apparatus also utilizes a portable main operating unit constructed to fit within a pouch or carrying case worn by the patient. In operation, at least one ultrasonic transducer and at least one electromagnetic coil are activated by transmitting control signals to the placement module from the main operating unit. The activation of the at least one ultrasonic transducer causes ultrasonic waves to be propagated toward the treatment area which are modulated by electrostatic and magnetic forces generated by the at least one electromagnetic coil. The activation of the at least one ultrasonic transducer and the at least one electromagnetic coil may be performed at the same time or at different times for varying periods.

The present invention is directed to prodrugs of hydroxamic acid based histone deacetylase (HDAC) inhibitors, e.g., suberoylanilide hydroxamic acid (SAHA). The prodrugs are acylated derivatives having increased aqueous solubility and cellular permeability as compared with the free hydroxamic acid, and are useful for inhibiting HDACs, and for selectively inducing terminal differentiation, cell growth arrest and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the prodrugs of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The prodrugs of the invention are also useful in the prevention and treatment of thioredoxin (TRX)-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases.

The invention provides compositions, pharmaceutical preparations and methods for increasing activity (e.g., ion transport) of the mutant cystic fibrosis transmembrane conductance regulator protein (mutant-CFTR), e.g., ΔF508 CFTR, G551D-CFTR, G1349D-CFTR, or D1152H-CFTR, that are useful for the treatment of cystic fibrosis (CF). The compositions and pharmaceutical preparations of the invention may comprise one or more phenylglycine-containing compounds or sulfonamide-containing compounds of the invention, or an analog or derivative thereof.

Provided herein are peptidomimetic macrocycles and methods of using such macrocycles for the treatment of disease.

The present invention relates to non-activated Wnt inhibition polypeptides (WIPs) containing: (a) a protein transduction domain (PTD) which enables said WIPs to permeate a cell membrane without the aid of a cell membrane receptor; and (b) a Wnt antagonist domain which is inactive by itself, but is activated in mammalian cells and then secreted out of the cells to function to inhibit Wnt signal transduction. Also, the invention relates to a method for preparing said non-activated WIPs, and a pharmaceutical composition containing said WIPs as active ingredients. Said non-activated WIPs can be produced in large quantities through the culture of bacteria such as E coli., and are biochemically inactive before being administered into the human body, and thus the production cost thereof is only one several tenths of that of previously known active proteins (sFRPs, DKKs, etc.) having uses similar thereto, and the isolation/purification and handling/administration processes thereof are significantly simple and convenient. When said non-activated WIPs are administered in vivo, they will have the effects of inhibiting the invasive growth and metastasis of cancer cells and treating immune diseases, such as rheumatoid arthritis by pharmacological mechanisms different from those of the previously known sFRPs or DKKs.

The invention relates to a novel broad-spectrum anti-inflammation analgesic drug for external use. The invention discloses a main compound extracted from mangosteen:Garcinia mangostana, i.e. mangostin, the mangostin is taken as the main active component and can be externally used for curing and preventing various acute and chronic ophthalmology and otorhinolaryngology inflammation, trauma and other symptoms after matching proper solvent or other preparations, and has the actions of excellent anti-inflammation, swelling reducing, abirritation, rapid hemostasis, affected part healing and the like. The content of the mangostin is between 0.1 and 99.8 percent and can be separately used or used by being matched with other substances, and the product overcomes the defects in the prior drug for curing the diseases, such as poor effect, high recurrence rate, side-effect and the like, and is the efficient and broad-spectrum new drug with anti-inflammation, rapid abirritation, non-toxicity, no side-effect and enhanced immunity.

The invention relates to a novel broad-spectrum anti-inflammation analgesic drug for curing various oral diseases. The invention discloses a main compound extracted from mangosteen:Garcinia mangostana, i.e. mangostin, the mangostin is taken as the maim active component and combined with the commonly-used filling agents in various pharmaceutical industries to be prepared into various dosage forms or as drugs, health care products, food additives and the like, and the mangostin can be internally and externally used for ulcerative stomatitis, pharyngitis and the like, and also can be used for preening and curing the oral diseases, for example, the benign and malignant tumors of oral cavity. The content of the mangostin is between 1.2 and 99.8 percent, can be separately used or used by matching other substances, and also can be used for preventing and curing the oral diseases of animals. The product overcomes the defects in the prior drug for curing the oral diseases, such as poor effect, irritability, high recurrence rate, side-effect and the like, and is the efficient and broad-spectrum new drug with anti-inflammation, rapid abirritation, non-toxicity, no side-effect and enhanced immunity.

A pentamethine cyanine fluorescent dye with N-substituting at β-position of conjugated chain is disclosed. The dye reacts with biosubstrate including protein, liposome and DNA, and shows excellent selectivity. It has good living cell membrane permeability and shows good selectivity in living cell staining In addition, the dye has good stability and low background fluorescence, and can be used together with other fluorescent dyes having consistent wavelengths for single-channel excitation and multi-channel detection. The dye can be used in the fields of protein labeling and detecting, fluorescence immunoassay and living cell selective imaging and the like.

The invention provides carrier protein, recombinant expression vector, an exosome and a preparation method and application of the exosome. Foreign protein can be carried into the exosome efficiently through fusion of the carrier protein with the foreign protein. Through the recombinant expression vector, a to-be-expressed foreign protein peptide fragment gene sequence is inserted into polyclonal sites of the recombinant expression vector, so that efficient and directed expression of the foreign protein in the cell exosome is achieved; meanwhile, the invention also provides the preparation method of the exosome for carrying the foreign protein, foreign gene can be brought into the exosome effectively, and simple and easy operation, a stable process and good applicability are achieved; and the exosome prepared by using the preparation method contains the foreign protein, has good cell permeability and highly efficiency of cell transfection, the activity and efficacy of the foreign protein can be developed at the same time, and a broad application prospect is achieved.

The present invention relates to methods of treating or decreasing the likelihood of developing a disorder associated with immune misregulation, such as, an autoimmune disorder, or viral or virus-associated disorder in a subject including administering to the subject a composition comprising an activator of a CCCH zinc finger-containing PARP, such as, PARP13 or PARP12. The present invention also relates to methods of treating a TRAIL-resistant disorder, such as, TRAIL-resistant cancer including administering to the subject a composition comprising an activator of a CCCH zinc finger-containing PARP, such as, PARP13 or PARP12. The present invention further relates to methods of modulating a CCCH zinc finger-containing PARP-RNA interaction including contacting a CCCH zinc finger-containing PARP protein or a CCCH zinc finger-containing PARP fusion protein with a CCCH zinc finger-containing PARP activator.

The invention provides compositions, pharmaceutical preparations and methods for increasing activity of a mutant cystic fibrosis transmembrane conductance regulator protein (mutant-CFTR). The compositions pharmaceutical preparations and methods are useful for the study and treatment of disorders associated with mutant-CFTR, such as cystic fibrosis. The compositions and pharmaceutical preparations of the invention may comprise one or more bithiazole-containing compounds of the invention, or an analog or derivative thereof.